Success Metrics

Active Trials
2(33%)

Phase Distribution

Ph phase_2
1
17%
Ph early_phase_1
3
50%
Ph phase_1
2
33%

Phase Distribution

5

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Early Phase 1First-in-human
3(50.0%)
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Other(2)

Detailed Status

Recruiting2
unknown2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Early Phase 13 (50.0%)
Phase 12 (33.3%)
Phase 21 (16.7%)

Trials by Status

recruiting233%
unknown233%
not_yet_recruiting233%

Recent Activity

2 active trials
Showing 5 of 6
not_yet_recruitingearly_phase_1

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07727668
not_yet_recruitingphase_2

A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

NCT07713459
recruitingphase_1

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

NCT07319676
recruitingearly_phase_1

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

NCT07441525
unknownearly_phase_1

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

NCT05248048
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07727668Early Phase 1

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Not Yet Recruiting
NCT07713459Phase 2

A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Not Yet Recruiting
NCT07319676Phase 1

Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas

Recruiting
NCT07441525Early Phase 1

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

Recruiting
NCT05248048Early Phase 1

NKG2D CAR-T Cells to Treat Patients With Previously Treated Liver Metastatic Colorectal Cancer

Unknown
NCT04846439Phase 1

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Unknown

All 6 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
6